Update on the Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding

Sophie Restellini\textsuperscript{a,b} Luc Biedermann\textsuperscript{c} Petr Hruz\textsuperscript{d} Christian Mottet\textsuperscript{e} Annick Moens\textsuperscript{f} Marc Ferrante\textsuperscript{f} Alain M. Schoepfer\textsuperscript{g} on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology

\textsuperscript{a}Division of Gastroenterology and Hepatology, University Hospital of Geneva, Geneva, Switzerland; \textsuperscript{b}Division of Gastroenterology, McGill University Health Center, Montreal, QC, Canada; \textsuperscript{c}Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland; \textsuperscript{d}Division of Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland; \textsuperscript{e}Division of Gastroenterology and Hepatology, Cantonal Hospital Sion, Sion, Switzerland; \textsuperscript{f}Division of Gastroenterology and Hepatology, University Hospital Leuven, Leuven, Belgium; \textsuperscript{g}Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland

Keywords
Pregnancy · Inflammatory bowel disease · Breastfeeding

Abstract
Inflammatory bowel disease (IBD) affects patients during their peak reproductive years. This raises important questions, in both patients and healthcare providers, regarding conception, pregnancy, and breastfeeding. Lack of information and insufficient communication among healthcare providers can leave patients with limited information and even contradictory advice. Given the fact that pregnant and/or breastfeeding IBD patients are excluded from clinical studies the evidence on many questions related to pregnancy and postpartum period is limited. However, there exists increasing data from case series and cohort studies that allows to provide clinical guidance. The overarching concept is that optimizing the mother’s health is critical for optimizing the health of the unborn child and benefit of continuing medical therapy in IBD during pregnancy outweighs possible risks in most instances. This paper provides an up-to-date systematic review of the literature on IBD in pregnancy and proposes guidance to questions frequently encountered by healthcare professionals.

Introduction

Inflammatory bowel disease (IBD) is represented by Crohn’s disease (CD) and ulcerative colitis (UC). The peak age onset of these diseases coincides with childbearing years and approximately 25% of patients will have their first child after being diagnosed with IBD [1]. These diseases may therefore have an impact on fertility, pregnancy, and lactation.

Managing IBD during pregnancy can be challenging for healthcare providers since the health of both the mother and the fetus must be considered to take the optimal therapeutic decision. Control of disease activity is
crucial, especially at the time of conception, as uncontrolled disease is associated with higher risks of adverse pregnancy outcomes for both, the mother [2, 3] and the fetus [4–8].

Many concerns among IBD patients exist regarding the impact of the disease during pregnancy and the consequences on the child. A report suggested that 50% of women with IBD were worried about infertility, one-fourth believed that it was more important to tolerate symptoms than to expose the fetus to their treatment, one-third believed that any medications given for IBD would be dangerous for their child, and three-fourths were concerned about transmitting the disease to their offspring [9–11]. These concerns can explain why certain women stop their treatment before conception or during pregnancy and lactation, despite the increasing evidence from recent studies confirming the benefit of continuing medical therapy in IBD during pregnancy [12–19].

Counseling patients during this emotional and important period of their lives is important. The management should be multidisciplinary including gastroenterologist and IBD nurse, obstetrician, primary care provider, pediatrician and if necessary surgeon. Communication between these care providers is crucial to avoid ambivalent or even contradictory counseling, which represents an extra source of anxiety for patients as well as potentially suboptimal adherence.

In 2015, The European Crohn’s and Colitis Organisation published the second consensus on reproduction and pregnancy in IBD, which includes mainly data published until 2013 [20]. Important concepts have emerged recently from case-control and large cohort studies. This article seeks to incorporate up-to-date evidence relating to the management of IBD before conception, during pregnancy, and the postpartum period.

Impact of IBD on Fertility

Patients with IBD have fewer children compared to the general population, which is partly explained by the choice of some patients not to have children. Voluntary childlessness is reported in 17% of women with IBD compared to 6% of women in the general population [21]. This choice results largely from fears that are often unjustified [22], reinforcing the importance of accurate counseling in this population to help them make their decision. A systematic review of 11 studies found no increased rate of infertility issues in women and men with IBD in remission and without a history of surgery [23]. However, the impact of IBD activity and certain treatments is important for both men and women regarding fertility and pregnancy outcomes.

Women

Medical therapy for IBD, including all biologic therapies, steroids, thiopurines, methotrexate, and mesalazine, does not decrease fertility [24–27]. However, women with active IBD may have decreased fertility [28–30] related to dyspareunia in patients with severe perianal or pelvic disease, fallopian tube occlusion secondary to pelvic adhesions, and ovarian dysfunction related to chronic illness or nutritional deficiencies [11]. Evidence suggests that patients having undergone proctocolectomy with ileal-pouch anal anastomosis (IPAA), proctectomy, and permanent ostomies are at increased risk for infertility. The decrease of fertility is mainly due to inflammation and scarring of the fallopian tubes [31–33]. Choosing a laparoscopic technique compared to laparotomy probably decreases infertility risk, and there is therefore no reason to avoid important surgery because a patient wants to be pregnant [34, 35]. Inability to conceive for 6 months should lead to referral for infertility evaluation, especially if there is a history of open pelvic surgery [36]. IBD women who have undergone IPAA have a success rate for in vitro fertilization comparable to those without IBD or with IBD but without surgery [37].

Men

Less is known about the impact of disease activity and IBD specific medications on men’s fertility and pregnancy outcome. A large internet-based voluntary cohort of IBD patients suggested that ensuring optimal control of disease is also important in male patients attempting to have children [38]. Men reported difficulties in conceiving more often when they had active or recently active disease. This association is probably explained by several factors such as decrease of desire for sexual activity related to anxiety and depression, effect of inflammation, and/or adverse effects of medications on semen characteristics. Several drugs may interfere with motility or sperm count. Sulfasalazine causes dose-related decrease in both sperm count and motility that is reversible. It should therefore be replaced by other 5-ASA formulations in men wishing to procreate [39]. Corticosteroids can cause a reversible decrease in sperm motility and concentration, but this observation does not seem to affect fertility in men [25, 40]. Methotrexate (MTX) is contraindicated due to its teratogenicity and risk of oligospermia, which is reversible 4–5 months after stopping the
drug [41, 42]. No evidence of effect on fertility outcomes is described for either thiopurine or antitumor necrosis factor (TNF) used by the father at the time of conception, although it has not been extensively examined [43–46]. Male patients suffering from UC who undergo IPAA may experience erectile dysfunction and retrograde ejaculation, also having surgery done at specialized center with laparoscopic approach help lowering the risks [47, 48].

Effect of Pregnancy on the Course of IBD

Risk of relapse during pregnancy in IBD women with stable disease is approximately 30%, which is similar to nonpregnant patients [7, 49, 50]. Conversely, two-thirds of patients with active disease at conception will have persistent active disease during pregnancy [2, 51]. Pregnancy also seems to lower the risk of long-term disease relapse [52, 53].

Effect of IBD on pregnancy, Fetal, and Neonatal Outcomes

Data on incidence of fetal abnormalities are conflicting, but reported risks are low [10, 51, 54]. Current evidence suggests that most of the time women who have quiescent disease before pregnancy have pregnancy outcomes similar to women without IBD. A 2-fold increased risk of low gestational weight compared with non-IBD patients has been reported in cohort studies [55]. Active disease is associated with higher rates of adverse outcomes such as fetal loss and stillbirth, preterm delivery, low birth weight, small for gestational age, thromboembolic events, cesarean section, increased neonatal intensive care admission, and low APGAR score [56, 57]. Adverse events result also on the degree of activity and its timing during pregnancy. It is difficult to determine whether disease activity itself or other confounding factors as discontinuation of treatments influence the increased risks. As such, it is recommended to control the disease prior to conception and to keep the mother in remission and well-nourished during pregnancy.

Monitoring of Disease Activity during Pregnancy

The diagnosis of active disease in pregnant IBD patients can be tricky as biological parameters such as C-reactive protein (CRP), hemoglobin concentration, erythrocyte sedimentation rate, and serum albumin are affected by pregnancy [51]. To take appropriate decisions and obtain and maintain remission, its crucial to carefully monitor patients during the prenatal period.

Endoscopy

Recent data suggest that endoscopy is relatively safe during pregnancy. It is contraindicated only in obstetric complications such as placentation abruption, ruptured membranes, or eclampsia. If endoscopy is necessary, the indication should be strong, and the procedure performed by experienced endoscopists to decrease the time of the procedure. Whenever possible, the procedure should be postponed after the first trimester because of the organogenesis. Pregnant women should be positioned in left lateral position or left pelvic tilt to avoid aortic and vena cava compression. An unsedated flexible sigmoidoscopy can be done in any trimester of pregnancy. Colonoscopy should be done with obstetric anesthesia monitoring. Benzodiazepines should be avoided, but propofol is considered safe during pregnancy, also it should preferably not be administered during the first trimester due to insufficient data. Fetal heartbeat should be detected before and after endoscopy and obstetric support should always be available.

Imaging

The safest methods of imaging during pregnancy remain ultrasound and magnetic resonance imaging. However, the view of abdominal contents with ultrasound can be limited especially in advanced gestation. When ultrasound results are inconclusive or for more complex cases magnetic resonance imaging without contrast can be proposed. In the absence of safety data, gadolinium is contraindicated during pregnancy. Abdominal X-ray and computed tomography should be avoided where possible because of concerns about side effects of irradiation on the fetus.

Biomarkers of IBD Activity during Pregnancy and Therapeutic Drug Monitoring

CRP and fecal calprotectin (FC) are helpful noninvasive markers used in IBD patients with relatively good correlation with disease activity. Also their accuracy and correlation with activity during pregnancy have not been well established [58–61], increasing body of evidence suggests, that FC may serve a reliable biomarker in all gestational periods and is less likely being prone to alterations as CRP.

A prospective evaluation of 30 pregnant women taking thiopurines found that maternal thiopurine metabolism changed during pregnancy, with 6-thioguanine concentration decreasing and 6-methylmercaptopurine concen-
tation increasing as pregnancy progressed [62]. No maternal biochemical toxicities resulted from this shift, and thiopurine metabolism reverted to baseline after delivery. Few data are available on maternal serum levels in pregnancy. A small sample size study by Seow et al. [63] observed that infliximab (IFX) levels increased during pregnancy while adalimumab (ADA) levels remained stable. A recent prospective single-center cohort study suggested that ADA may be continued longer during pregnancy because transportation over the placenta is lower than for IFX [64]. Interestingly, a recent work including 12 patients on IFX and 4 patients on ADA with at least 2 intrapartum measurements suggested that maternal drug levels remain stable in patients on stable dosing of IFX or ADA in remission during pregnancy [65]. Further data are required to determine if and how pregnancy influences the pharmacokinetics of biologic treatments. Experts recommend in clinical practice to check maternal trough levels during the second trimester and adapt dosing appropriately during the third trimester in order to give the maximum interval possible before delivery [27].

**Drug Safety in Pregnancy**

Many women with IBD will stop their medication before or during pregnancy because of their concerns about drug safety, which may lead to increased risk of relapse and undesirable pregnancy outcome [66, 67].

Pregnant and breastfeeding women are typically excluded from clinical trials, and randomized controlled trials on safety data on medications are lacking. However, with multiple registry, cohort, and database sources, the safety of IBD medications (except for methotrexate) has been supported in the recent literature for conception, pregnancy, and lactation, even if the overall evidence is still poor and the strength for most of the recommendations still weak.

Recently, the US Food and Drug Administration has abandoned the product letter categories (A, B, C, D, and X) and replaced them by detailed subsections (human, animal, and pharmacological) describing available information on potential risks and benefits for the mother, the fetus, and breastfed children [27] (Table 1).

**Antibiotics**

Metronidazole and ciprofloxacin are commonly prescribed in IBD patients. A meta-analysis of first-trimester quinolone exposure did not detect any particular increased risk [68]. Conversely, the use of metronidazole is controversial in pregnancy because 1 case-control study suggested a possible increased risk for oral clefts when used in the first trimester. However, 2 meta-analyses and 1 systematic review found no increased risk for congenital anomalies [69]. Amoxicillin-clavulanic acid is considered to be safe during pregnancy [70]. Rifaximin should be avoided in human pregnancy as no safety data have been published in human pregnancy and animal studies revealed evidence of teratogenicity. Several large trials are ongoing regarding the use of probiotics in pregnancies, and preliminary results reported improvement in certain outcomes including preterm birth, allergies, and infections in children [71].

**Aminosalicylates**

Aminosalicylates are commonly used to treat flares of mild to moderate UC and for maintenance of remission. Aminosalicylates, including sulfasalazine, are considered safe in pregnancy up to 3 g/day and should be continued in patients in whom remission has been obtained prior to conception [72, 73].

Sulfasalazine interferes with folate synthesis by inhibiting dihydrofolate reductase and pregnant women taking sulfasalazine should receive high-dose folic acid supplementation (2 mg/day) to prevent neural tube defects [74]. Mesalamine derivatives can be continued during pregnancy with the exception of Asacol that contains in its coating dibutyl phthalate, which has been associated with congenital anomalies in animals at doses >190 times the therapeutic human dose [75]. Mesalamine enemas and suppositories may be continued without any risk.

**Corticosteroids**

Corticosteroids may be necessary during pregnancy to treat disease flares.

Older studies suggested that exposure to steroids during the first trimester may be associated to an increased risk of cleft lip and palate development [76]. This observation was not reported in a large Danish cohort of patients, who were exposed to any form of corticosteroids during the first trimester (OR 1.05; 95% CI 0.80–1.38) [77]. In the Pregnancy in IBD and Neonatal Outcomes (PIANO) registry, the use of steroids was associated with an increased risk of certain maternal-fetal adverse events, such as preterm birth (OR 1.8; 95% CI 1.0–3.1), low birth weight (OR 2.8; 95% CI 1.3–6.1), and gestational diabetes (OR 2.8; 95% CI 1.3–6.0) [78]. Therefore, patients on corticosteroids during pregnancy should receive blood pressure surveillance, glucose tolerance testing, and serial growth scans in the third trimester. Literature on the safe-
Table 1. IBD treatment during pregnancy (adapted from [27] and [114])

<table>
<thead>
<tr>
<th>Drug</th>
<th>Pregnancy safety</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibiotics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amoxicillin with clavulanic</td>
<td>Low risk. Limited data</td>
<td>Preferred antibiotic during pregnancy</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>Low risk. Animal data reported anomalies</td>
<td>Short courses for perianal disease</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>Low risk. Avoid first trimester. Possible risk of cleft lip</td>
<td>Short courses for perianal disease</td>
</tr>
<tr>
<td>Rifaximin</td>
<td>Teratogenicity described in animal models</td>
<td>Avoid</td>
</tr>
<tr>
<td><strong>Aminosalicylates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balsalazine</td>
<td>Low risk.</td>
<td>Maintain prepregnancy dose</td>
</tr>
<tr>
<td>Mesalamine</td>
<td>Low risk. Exception: asacol contains dibutylphthalate coating reported to be teratogenic in animal models</td>
<td>Maintain prepregnancy dose. Switch Asacol to another mesalamine agent with equivalent dose</td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>Low risk.</td>
<td>Maintain prepregnancy dose. Increase folic acid to 2 mg daily</td>
</tr>
<tr>
<td><strong>Corticosteroids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budesonide</td>
<td>Low risk.</td>
<td>Maintain prepregnancy dose</td>
</tr>
<tr>
<td>Prednisone</td>
<td>Moderate risk. Mother: possible increase risk of gestational diabetes, adrenal insufficiency, premature rupture of membranes. Child: possible increase risk of orofacial cleft (first-trimester exposure), preterm birth, infections</td>
<td>Short courses. Use steroid-sparing agents when possible</td>
</tr>
<tr>
<td><strong>Immunomodulators</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Possible but limited data with reported increased risk of pregnancy complications, preterm birth, low birth weight</td>
<td>Maintain prepregnancy dose</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Contraindicated: teratogenic and abortifacient</td>
<td>Women must stop the drug 3–6 months before attempting conception</td>
</tr>
<tr>
<td>Thiopurines (azathioprine, 6-mercaptopurine)</td>
<td>Low risk in monotherapy Increased risk of infant infections in combination therapy</td>
<td>Maintain prepregnancy dose in monotherapy If patient on combotherapy is in clinical and endoscopic remission with adequate trough levels, consider stopping thiopurine and continuing biologic monotherapy No introduction during pregnancy due to long delay of action and unpredictable risk of developing medullary suppression or pancreatitis</td>
</tr>
<tr>
<td><strong>Small molecules</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>Human data very limited</td>
<td></td>
</tr>
<tr>
<td><strong>Biologics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-TNF-α</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFX</td>
<td>Low risk in monotherapy</td>
<td>Maintain prepregnancy dosing. Consider decreasing the dose or increasing interval of administration depending on second trimester trough levels. Continue dosing until 8–10 week before delivery</td>
</tr>
<tr>
<td>ADA</td>
<td>Low risk in monotherapy</td>
<td>Maintain prepregnancy dosing. Continue dosing until 3–4 week before delivery</td>
</tr>
<tr>
<td>GM</td>
<td>Low risk in monotherapy</td>
<td>Maintain prepregnancy dosing. Continue dosing until 4–6 week before delivery</td>
</tr>
<tr>
<td>CZP</td>
<td>Very low risk. Does not actively cross placenta</td>
<td>Maintain prepregnancy dosing. Continue scheduled dosing through pregnancy</td>
</tr>
<tr>
<td><strong>Anti-integrin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VDZ</td>
<td>Low risk in monotherapy. Limited data</td>
<td>Maintain prepregnancy dosing. Continue dosing until 8–10 week before delivery</td>
</tr>
<tr>
<td><strong>Anti-interleukins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UST</td>
<td>Low risk in monotherapy. Limited data</td>
<td>Maintain prepregnancy dosing. Continue dosing until 8–10 week before delivery</td>
</tr>
</tbody>
</table>

IBD, inflammatory bowel disease; IFX, infliximab; ADA, adalimumab; GM, golimumab; CZP, certolizumab pegol; VDZ, vedolizumab; UST, ustekinumab.
The use of steroids is possible during pregnancy, and the benefit of disease control outweighs the risk of exposure. It is difficult to separate the effect of disease activity from a side effect of the drug as corticosteroids use reflects that disease is not in remission. Prolonged exposure should be avoided, and this drug should not be considered as a maintenance strategy treatment. Methylprednisolone and hydrocortisone should be the molecules of choice as their increased placental metabolism reduces the risk of fetal exposure compared to dexamethasone or betamethasone.

**Immunomodulators**

MTX is an antimetabolite that blocks the synthesis of thymidine. Exposure to MTX during organogenesis can lead to multiple malformations, mainly of limbs and skull known as methotrexate embryopathy. This drug is therefore contraindicated during conception and pregnancy. A woman of childbearing age on MTX should receive effective contraception. If accidentally conception occurs, therapeutic abortion should be discussed, but not necessarily performed [20]. In addition, after discontinuation of treatment, women should wait 3–6 months before attempting to become pregnant because of the long half-life of terminal elimination of the drug [80, 81].

Thiopurines (azathioprine and 6-mercaptopurine) interfere with the synthesis of nucleic acid causing chromosomal damage. These drugs have been reported to be teratogenic in animal studies at doses similar to those used in humans, but administration in these studies was intraperitoneal or parenteral, which significantly increased the bioavailability of the drug [82–86]. However, recent studies agreed on the safety of thiopurines both on the conventional studies, 301 were women of childbearing age. Eleven cases of maternal exposure and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of paternal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identified. Outcomes included 15 healthy newborns and 14 cases of prenatal exposure to tofacitinib (doses of 5 or 10 mg twice daily) were identifi...
Biologic Agents

Biologic agents are IgG or fragments that are to a various extent actively transported across the placenta by the neonatal Fc receptor, which becomes functional at week 13 of gestation [92]. Eighty percentage of transfer occurs during the third trimester and fetal IgG concentrations are increased logarithmically from gestational week 20 to delivery [93–95]. As a consequence of this active transport across the placenta, cord blood biologics concentrations can exceed maternal levels by up to 4-fold at birth and may be detectable in children for up to 12 months [66], raising concern about possible adverse effects on the development of the immune system of the infant [96]. Organogenesis occurs before transplacental anti-TNF drug transfer and to date no association was observed between congenital malformations and biologics.

Anti-TNF Agents

The 4 anti-TNFs approved in IBD are IFX, ADA, certolizumab pegol (CZP), and golimumab. CZP differs from the others in that it is a pegylated Fab fragment anti-TNF agent. This results in clinically insignificant drug levels in infants. Series on >100 IBD patients exposed during pregnancy to IFX [97], ADA [98], and CZP [99] found no adverse effect on pregnancy outcomes. Golimumab is supposed to have a similar safety profile. To date, no evidence was found for an association between treatment with TNF-α inhibitors for IBD in pregnancy and risk of congenital anomalies compared with disease-matched pregnancies. More than 500 women in the ongoing PIANO registry have been exposed to the aforementioned anti-TNF medications during pregnancy, and no increased risk with adverse pregnancy outcomes was observed [88]. A systematic review by Nielsen et al. [94] was consistent with these finding with no miscarriages, preterm deliveries, stillbirth, low birth weight, congenital malformations, and/or infections noted even when the drug was administered during the third trimester. A recent meta-analysis of 5 studies with 1,216 IBD patients neither found an increase in adverse outcomes in women taking anti-TNF therapy compared with unexposed controls (OR 1.00; 95% CI 0.72–1.41), including preterm delivery (OR 1.00; 95% CI 0.62–1.62), low birth weight (OR 1.05; 95% CI 0.62–1.78), and congenital anomalies (OR 1.10; 95% CI 0.58–2.09) [100]. However, women receiving an anti-TNF in combination with thiopurine had higher risk of preterm delivery (OR 2.4; 95% CI 1.3–4.3) and pregnancy complication (OR 1.7; 95% CI 1.0–2.2) compared with unexposed women [100]. These observations reflect also probably that these patients had a more active disease. In addition, a risk of delayed infant infections was reported.

Anti-integrin Agents

Vedolizumab (VDZ) is a gut-selective humanized IgG-1 monoclonal antibody to α4β7 integrin approved for both CD and UC. A reproductive study of VDZ in pregnant primates demonstrated no evidence of adverse effects on development after intravenous administration of VDZ at doses 20 times the equivalent of those recommended for humans [101]. To date, we have limited data available on human pregnancy safety. A recent case series described the evolution of 24 VDZ treated pregnancies. No new safety concerns for pregnancy outcomes in females directly or indirectly exposed to VDZ were observed [102]. An international retrospective study reported pregnancy and neonatal complication in 24 women treated with VDZ with 12 live births, 4 spontaneous abortions, and 5 elective abortions [103]. More recently, the same group conducted a retrospective European study where gastroenterologists were asked to report all VDZ exposed pregnancies as well as neonatal outcomes through an electronic case report form. There was no difference in miscarriage rates between the VDZ exposed group and a control group of patients exposed to anti-TNF (16 vs. 13%, p = 0.71) or a control group of patients neither exposed to immunosuppressors nor to biologics (16 vs. 10%, p = 0.236). After exclusion of patients with active disease, the number of miscarriages was similar between VDZ group and patients in other groups [104].
Therefore, active disease in pregnancy rather than drug effect seems to have been the driver of this adverse pregnancy outcome. Experts suggest to use VDZ for women of childbearing age if indicated. Still, if the childbearing age woman is bionaive, most data are available with anti-TNF agents, and therefore maybe anti-TNF, and especially CZP are most appropriate as first-line treatment option.

Anti-Interleukin IL-12–23

Ustekinumab is an IgG1 monoclonal anti-interleukin 12–23 antibody approved for psoriasis, psoriatic arthritis, and more recently for CD. A series of 26 exposed pregnancies reported 5 spontaneous abortions (19%), a rate that is similar to the general population [105]. A cohort of 226 women treated with Ustekinumab for psoriasis or CD will be presented this year and no specific signal is reported to date compared to the general population [106].

DOI: 10.1159/000502886
To Stop or Not to Stop Treatment during Pregnancy: Is the Debate Over?

The strategy regarding the discontinuation of anti-TNF therapy early during pregnancy poses several problems. Stopping treatment is associated with a higher risk of a flare during pregnancy and during the postpartum period and increase in the risk of developing antibodies due to lower trough levels leading possibly to loss of response to the drug after resuming treatment.

Discontinuation of anti-TNF-α during pregnancy may be considered under certain circumstances in patients who are at very low risk of relapse with an objective sustained endoscopic remission since <6 months before conception, no previous loss of response to anti-TNFs or need for dose optimization, appropriate therapeutic levels before conception, no hospitalization in the last 3 years, and no prior bowel resection [107].

As mentioned previously, there is no evidence that continuing anti-TNF therapy during pregnancy has a negative impact on the pregnancy or children’s outcomes [108, 109]. In patients with active disease during the second trimester, the benefit of continuing anti-TNF therapy during the third trimester outweighs the potential risk [26, 88, 89]. To minimize transplacental transfer near the time of delivery, biologic dosing can be adjusted to achieve trough or lowest serum drug concentrations at the estimated date. Although this strategy is probably safe, we do not have solid data to confirm it, and this is why most experts agree to stop biological therapies around week 20 in patients in remission (Table 1) [26].

Delivery Mode

Women with IBD have twice as many cesarean deliveries as women in the general population [31]. Most of the time, a caesarean section is proposed or requested because of unjustified fears on the part of patients or care providers. Also there is no contraindication to vaginal delivery in the majority of cases [110], a healthy IBD patient should be able to have a successful vaginal delivery. Episiotomy should be avoided whenever possible as it can trigger perianal disease. Women with active perianal or rectal disease involvement and open rectovaginal fistula at the time of delivery should however have planned cesarean section [111]. In this population cesarean delivery should be performed by a senior obstetrician in order to decrease the risk of intraoperative organ injury. IPAA is a relative contraindication for vaginal delivery.

Postpartum Period and Lactation

Postpartum

The risk of disease relapse is higher in the postpartum period. This risk is mainly a consequence of discontinuation of IBD therapies during pregnancy with extended period of time before resuming treatment during the postpartum period [112]. In the pregnant IBD population from the French GETAID cohort, 14% of women who discontinued anti-TNF treatment before week 30 of gestation while in remission experienced a relapse during the last trimester of pregnancy with a complicated disease course in 75% of cases (8 cases of prematurity and 1 case of colectomy for severe acute colitis) and a third of them had a flare during the early post-partum period before week 3. The relapse rate was 26% in the early postpartum period among women who continued anti-TNF therapy throughout pregnancy because of active disease [113].

In the absence of infectious complications, biological treatment could be resumed 24 h after vaginal delivery and 48 h after cesarean delivery [27]. For weight-based dosing treatments, it is usually recommended to consider the mother’s weight before pregnancy. The dose will then be adjusted according to several factors including disease activity, possible persistent weight gain postpartum and serum concentrations. Other IBD treatments can be continued in the postpartum period. MTX can be restarted postpartum if the mother is not lactating [114].

After a cesarean delivery, patients are at higher risk of developing an ileus, especially patients with IPAA in whom the pouch was manipulated during the delivery. Supportive measures and early feeding may decrease this risk [115]. Patients with an ostomy are more at risk of stoma complications during pregnancy and after delivery. It is recommended to avoid excessive weight gain during pregnancy and after cesarean section, simply covering the ostomy with gauze is sufficient to protect the operative field [116].

Lactation

A significant number of women with IBD do not breastfeed their children despite the fact that benefits of breastfeeding have been demonstrated to be substantial to both mother and child [117].

The relationship between breastfeeding and disease activity usually reflects the consequence of IBD therapies discontinuation, as 60% of women discontinued...
their medications in the postpartum period for fear of medication transmission in breast milk [66, 111]. In the PIANO registry, the breastfeeding rate was significantly lower in women on immunomodulators and biologic treatments [118]. Although, literature is sparse in this field and long-term safety data are missing, the vast majority of medications prescribed for IBD are either undetectable in breast milk or present in concentrations that would not be expected to harm the breastfeeding infant (Table 2) [114]. Clinicians can rely on LactMed, which is a free online database sponsored by the US National Library of Medicine, that provides reliable infor-

Table 2. IBD treatment and breastfeeding (adapted from [27] and [114])

<table>
<thead>
<tr>
<th>Drug</th>
<th>Breast milk drug concentration and safety</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibiotics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amoxicillin with clavulanic acid</td>
<td>Enters breast milk. Monitor child for diarrhea and rash</td>
<td>Compatible</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>Enters breast milk. Monitor child for diarrhea and rash</td>
<td>Compatible but delay feeding 3–4 h after dose</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>Enters breast milk, possible mutagenicity</td>
<td>Contraindicated</td>
</tr>
<tr>
<td>Rifaximinin</td>
<td>Unlikely to reach breastmilk. No human data</td>
<td>Avoid</td>
</tr>
<tr>
<td><strong>Aminosalicylates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poorly excreted into milk. Rare reports of diarrhea</td>
<td>Compatible. Maintain same dosing</td>
<td></td>
</tr>
<tr>
<td><strong>Corticosteroids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(budesonide, prednisone, prednisolone)</td>
<td>Dose-dependent levels in milk. Prednisolone preferred for high-dose therapy</td>
<td>Compatible but delay feeding 3–4 h after dose for doses &gt;20 mg</td>
</tr>
<tr>
<td><strong>Immunomodulators</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Variable, but breastfed infant receives &lt;2% of mother’s weight-adjusted dose</td>
<td>Probably compatible but infant levels should be monitored</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Low dose likely results in low milk concentration</td>
<td>Contraindicated based on concerns for high-dose exposure</td>
</tr>
<tr>
<td>Thiopurines (azathioprine, 6-mercaptopurine)</td>
<td>Low levels in milk and undetectable after 4 h</td>
<td>Compatible. Delay feeding for 4 h after dose recommended</td>
</tr>
<tr>
<td><strong>Small molecules</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>Unknown. No human data</td>
<td></td>
</tr>
<tr>
<td><strong>Biologics</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| IFX                           | Low levels in milk ≤ 0.5% of mother’s plasma concentration  
Peak excretion 1–4 day post infusion                   | Compatible. Maintain same dosing               |
| ADA                           | Low levels in milk <1% of mother’s plasma concentration  
Peak excretion 1–6 day postinjection                      | Compatible. Maintain same dosing               |
| GM                            | Low or undetectable levels in milk                                                                        | Compatible. Maintain same dosing               |
| CZP                           | Very low or undetectable levels in milk  
Peak excretion 0.5–2 day postinjection                       | Compatible. Maintain same dosing               |
| **Anti-integrin**             |                                                                                                           |                                               |
| VDZ                           | Low or undetectable levels in milk <1% of mother’s plasma concentration  
Peak excretion 3–7 day postinjection                          | Probably compatible. Maintain same dosing       |
| **Anti-interleukins**         |                                                                                                           |                                               |
| UST                           | Low or undetectable levels in milk  
Peak excretion 1 postinjection                               | Probably compatible. Maintain same dosing       |

IBD, inflammatory bowel disease; IFX, infliximab; ADA, adalimumab; GM, golimumab; CZP, certolizumab pegol; VDZ, vedolizumab; UST, ustekinumab.
mation on drugs and lactation. Treatments derived from mesalamine are generally found in the milk but are well tolerated. Only isolated cases of diarrhea were reported in exposed children. 5-ASA agents (mesalamine, balsalazide, and olsalazine) can therefore be continued during lactation. Those formulations are preferred to sulfasalazine due to the unknown side effects of drug metabolite, which are excreted into milk at concentrations that are higher than in the mother and known for hemolytic and antimicrobial properties. Corticosteroids low dose and thiopurines are detected in small amounts in the milk [119]. Some data suggest that higher dose of prednisone (>20 mg/day) can result in higher levels in the breastfed infant and cause temporary loss of milk supply. Thiopurines are not detected in breast milk 4 h from dosing. Although it is not absolutely necessary, some experts recommend avoiding breastfeeding 3–4 h after taking these medications in order to limit the amount of drug transmitted onto the child. In most studies, the concentrations of biological agents found in milk are minimal (<1% of serum concentration) as the drug is degraded in the stomach of the child and no harm from breastfeeding on biologic therapies has been described [120]. Data for anti-interleukin 12–23 and anti-integrin are very limited but due to limited transfer detectable and their monoclonal antibody molecular structures it is presumed that they are compatible with lactation [121, 122]. Women on tofacitinib should be replaced by another Mesalamine formulation (Fig. 1).

Preconception Counseling

IBD patients in childbearing age should always be asked if they have a pregnancy plan in the near future. In this way, the gastroenterologist will be able to take the time to reassure the patient about the safety of most treatments used during pregnancy and lactation. He will also have the opportunity to reassess disease activity and achieve remission before attempting conception. Laboratory analysis, dosage of FC, and endoscopy prior to conception, if endoscopic remission has not been assessed before, should be part of the workup. This is also a good moment to ensure that basic care has been provided such as screening for anemia and vitamin deficiency, vaccinations update, supplementation for folic acid, and smoking cessation. At this point, Asacol should be replaced by another Mesalamine formulation (Fig. 1).

Management during Pregnancy

The risk of adverse outcomes is increased in woman with IBD during the pregnancy, even if their disease is in endoscopic remission [123]. Therefore, close monitoring is recommended during pregnancy in this high-risk population.

In each trimester, FC and serum inflammatory markers, as well as gestational weight gain, should be monitored for evidence of disease activity and poor nutrition. If available, a trough level of biologic agent can be checked in the late second trimester to determine timing and dose of biologic agent in the third trimester. In the third trimester as well as in the postpartum, the pediatrician should be informed that live vaccines are contraindicated in infant exposed to biologic treatments. The management of flares would be similar to the nonpregnant patient with the exception that traditional serum markers of disease activity, such as sedimentation rate, hemoglobin, and albumin, are abnormal in pregnancy (Fig. 2).

Impact of IBD for the Baby

IBD and Heredity

Genetic risk of CD is higher than for UC in European cohort studies. Having multiple family members with IBD increases the risk for children with IBD. In monozygotic twins studies, 20–56% of CD and 6–19% of UC had concordance [124]. With maternal CD, incidence rate ratio for CD is 6.3 in offspring, and the absolute risk of an offspring developing CD is 2.7%. With maternal UC,
**Preconception assessment**

Disease assessment:
- Clinical assessment
- Objective assessment with at least biomarkers (CRP, FC)
- Consider endoscopy and imaging

Active disease:
- Discuss risks of infertility, worsening disease activity and consequences on pregnancy outcomes
- Delay conception and recommend contraception

Optimize maintenance medications:
- Confirm adherence
- Modify treatment to obtain remission

Inactive disease
- 3-month steroid-free remission prior to conception

MTX: STOP at least 3–6 months prior conception and switch to safer medication during pregnancy

Thiopurines and biologics:
- Continue same dosage (except for tofacitinib: avoid)

**Preconception counseling**

Discussion/education:
- Discuss fertility
- Discontinue teratogenic medications
- Iron and folic acid supplementation and ensure adequate caloric and vitamins levels
- Optimize management of comorbidities
- Update immunization status
- Cessation of tobacco, alcohol and illicit drugs
- Discuss risk/benefit ratio of IBD medication during pregnancy and lactation
- Discuss mode of delivery
- Discuss treatment plan with family doctor and obstetrician

**9 months follow-up**

**IBD in clinical remission**

- Check iron/B12 levels, adequate folic acid supplementation
- Nutrition consult if needed (short bowel, ostomy...)
- GI visit
- Labs: CBC, liver enzymes, albumin, CRP
- 5-ASA, thiopurines and biologics to be continue throughout pregnancy without interruption.

**Trimester 1**

- GI visit
- Labs: CBC, liver enzymes, albumin, CRP
- TDM and can time last dose in trimester 3 to deliver infant at presumed drug trough

**Trimester 2**

- Continue treatment
- Last dose of biologics based on TDM (cf table 1)

**Trimester 3**

- GI follow-up every 2 weeks
- Monitor labs, calprotectin
- Nutrition counseling
- Management of the flare:
  - GA <37 weeks: same medical therapy as usual to treat flare (steroids short period then Anti-TNF if naive or drug optimization)
  - GA ≥37 weeks: corticosteroid and consider deliver if non responder to steroids

**Active IBD**

- Vaginal: biologics can be resumed 24 h post delivery if no infection
- Cesarean: biologics can be resumed 48 h post-delivery if no infection.
- Measures to prevent ileus and wound infection.
- Anticoagulant prophylaxis for VTE

**Fig. 1.** Algorithm of care during preconception period (adapted from [114]). CRP, C-reactive protein; FC, fecal calprotectin; MTX, methotrexate; 5-ASA, 5-amino-salicylic acid; DPB, dibutyl phthalate; IBD, inflammatory bowel disease.

**Fig. 2.** Algorithm of care during pregnancy (adapted from [114]). IBD, inflammatory bowel disease; CRP, C-reactive protein; GI, gastroenterologist; CBC, complete blood count; TDM, therapeutic drug monitoring; GA, gestational age; VTE, venous thromboembolism; 5-ASA, 5-amino-salicylic acid.
this incidence rate ratio is 3.7 for UC in an offspring, and the absolute risk of an offspring developing UC is 1.6% [125]. When both parents have the disease the risk of developing IBD rises to 30% [114]. Currently, no genetic test is available to predict whether the child will develop IBD.

**Infection and Vaccination**

Parents and pediatricians should be vigilant about infections, especially if the child was exposed to combination of thiopurines and biologics. A systematic review of anti-TNF use during IBD pregnancies found no increased risk of infections in the first year of infant life [94]. However, individual cases of serious infection have been reported [47]. In the PIANO registry, there is 1 case of vertical histoplasmosis transfer involving a mother taking IFX 10 mg/kg every 6 weeks who had supratherapeutic IFX levels at birth. It is recommended to minimize unnecessary antibiotic exposure, as that may increase the risk of developing CD later in childhood. Clinically significant levels can be found in newborn infants for up to 6 months after birth. Avoidance of live vaccines in infants exposed to biologic therapy during the third trimester of pregnancy is recommended until at least after 6 months because significant levels can be found in infants up to 6 months after birth and may lead to clinically relevant neonatal immunosuppression. The rotavirus vaccine postdelivery is the only live vaccine administered before 6 months in certain country such as in the United States. The first dose should be administered before 15 weeks of age to be more effective.

**Mental Development**

No evidence suggests that babies born to mothers with IBD regardless of medication exposure have any developmental delays. Data on developmental milestones from the PIANO registry support the lack of negative impact of IBD treatments on development. Moreover, infants with higher anti-TNF drug levels at birth had statistically superior achievement of developmental milestones compared with infants with lower birth drug levels. The hypothesis of effects of inflammation in utero on the developing brain has been reported and pro-inflammatory mediators negatively influence both hippocampal neurogenesis and neuronal cytoarchitecture during brain development. The importance of good inflammatory control during pregnancy should therefore be emphasized when counseling women with IBD [126].

**Conclusions**

IBD affects patients during their peak reproductive years raising important questions, in both patients and healthcare providers, regarding conception, pregnancy, and breastfeeding. Lack of information and poor communication among healthcare providers can leave patients with limited information and contradictory advice. Although there are clear limitations to the evidence base in this area, expert groups have nonetheless provided clear guidance on how best to answer these questions. Gastroenterologists are a key resource to provide reassurance and guidance during this important period of patients’ lives, and they should work with other healthcare providers. The overarching concept is that optimizing the mother’s health is critical for optimizing the health of the child and benefit of continuing medical therapy in IBD during pregnancy outweighs possible risks in most instances.

**Acknowledgment**

None.

**Disclosure Statement**


**Funding Sources**

There is no funding to declare.

**Author Contributions**

Pregnancy in IBD

References


53 Restellini/Biedermann/Hruz/Mottet/Moens/Ferrante/Schoepfer

Digestion
DOI: 10.1159/000502886
Pregnancy in IBD


